Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia

A subcutaneous formulation of the anti‐CD20 antibody rituximab has been developed. Fixed‐dose subcutaneous rituximab delivers noninferior serum trough concentrations (C(trough)), ensuring similar target saturation and comparable efficacy/safety, to intravenous rituximab, but with simplified and shor...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibiansky, Ekaterina, Gibiansky, Leonid, Chavanne, Clarisse, Frey, Nicolas, Jamois, Candice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376135/
https://www.ncbi.nlm.nih.gov/pubmed/34110098
http://dx.doi.org/10.1002/psp4.12665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376135/
https://www.ncbi.nlm.nih.gov/pubmed/34110098
http://dx.doi.org/10.1002/psp4.12665

Ejemplares similares